US Orthopedic Biomaterial Market to Grow Strongly to $3.7 Billion by 2017 Resurgence in Growth in Bone Graft Substitutes, According to Millennium Research Group PR Newswire TORONTO, Jan. 30, 2013 TORONTO, Jan. 30, 2013 /PRNewswire/ --According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, demographic trends, a resurgence in the bone graft substitute (BGS) segment will help the US orthopedic biomaterial market to grow strongly to nearly $3.7 billion by 2017. (Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO) The BGS segment is still suffering from the effects of the sales decline of Medtronic's INFUSE product. Although it remains the highest-revenue product in this segment, INFUSE continues to face challenges associated with waning off-label use, which has historically made up a significant portion of the product's sales. There will, however, be a resurgence in the growth factor market, which will be driven in part by increasing uptake of Advanced Biologics' OsteoAMP growth factor product, along with Wright Medical Technology's Augment and Cerapedics' i-Factor products. The latter two are expected to be approved and launched before 2017. Cost containment measures at hospitals will curb this resurgence, however, and many surgeons will opt to use lesser-expensive alternatives, including orthopedic stem cell products and second-generation synthetics. "Although orthopedic stem cell products are facing some challenges in coverage due to a lack of robust clinical data, they will continue to see strong increases in use," said MRG Analyst Mashkur Reza. "With the launch of new products, such as Biomet's Cellentra, the demand for orthopedic stem cell products will continue to grow fairly strongly. Other competitors are more than likely to follow suit and will compete against the likes of Biomet and NuVasive, the latter of which leads the segment with its Osteocel product." Through 2017, the fastest-growing segment in the US orthopedic biomaterials market will be hyaluronic acid (HA) viscosupplementation, as patients increasingly opt for more convenient, and also more expensive, single-injection HA treatments. The cell concentration systems segment will also contribute to growth in the market. Millennium Research Group's US Markets for Orthopedic Biomaterials 2013 report includes unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for BGS, hyaluronic acid viscosupplementation, machined bone interbody devices, and cell concentration systems in the United States. About Millennium Research Group Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions. About Decision Resources Group Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com. All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Christopher Comfort Alex Jablokow Decision Resources Group Millennium Research Group 781-993-2597 617-599-8613 firstname.lastname@example.org email@example.com SOURCE Millennium Research Group Website: http://www.MRG.net
US Orthopedic Biomaterial Market to Grow Strongly to $3.7 Billion by 2017
Press spacebar to pause and continue. Press esc to stop.